<DOC>
	<DOCNO>NCT01284205</DOCNO>
	<brief_summary>The purpose study compare safety efficacy EN3348 ( MCC ) versus BCG first line treatment patient non-muscle invasive bladder cancer high risk recurrence progression .</brief_summary>
	<brief_title>First Line Comparative Study EN3348 ( MCC ) v BCG NMIBC</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>histologically confirm urothelial carcinoma bladder ( high grade Ta T1 papillary lesion , CIS ) histologically confirm diagnosis within 42 day study treatment life expectancy great 5 year ECOG performance status 2 less absence urothelial carcinoma involve upper urinary tract prostatic urethra within 12 month start study treatment current previous history muscle invasive bladder tumor ( &gt; T2 ) current previous history lymph node and/or distant metastasis bladder cancer current evidence squamous cell carcinoma , adenocarcinoma undifferentiated carcinoma bladder current systemic cancer therapy previous immunotherapy bladder cancer previous intravesical chemotherapy treatment contraindication use BCG know tolerance BCG history malignancy organ system within past 5 year ( exception basal cell squamous cell carcinoma , stage T1 prostate cancer , carcinoma situ cervix , colon polyp ) patient tolerate intravesical administration intravesical surgical manipulation ( cystoscopy biopsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>non-muscle invasive bladder cancer</keyword>
	<keyword>superficial bladder cancer</keyword>
</DOC>